GMAB

Genmab AS

27.20 USD
-0.04 (-0.15%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Genmab AS stock is up 5.43% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 5 July’s closed higher than June. 100% of analysts rate it a buy.

About Genmab AS

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases. The company markets DARZALEX, a human monoclonal antibody for the. treatment of patients with multiple myeloma (MM) and ofatumurnab for. multiple sclerosis (CLL) and multiple sclerosis. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers.

  • BTIG
    Thu Jun 27, 07:59
    buy
    confirm
  • HC Wainwright & Co.
    Thu Jun 27, 06:29
    buy
    confirm
  • HC Wainwright & Co.
    Thu Jun 20, 06:40
    buy
    confirm